Loading company…
Propanc Biopharma develops proenzyme-based cancer therapies aimed at limiting tumor recurrence and metastasis.
Founded in 2010 and based in Melbourne, Propanc Biopharma is developing PRP for solid tumors, with an initial focus on pancreatic, ovarian, and colorectal cancers. In November 2021, it raised USD 5.00 mn in a PIPE round from Dutchess Capital Management to support the program.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in